Adjunct bromocriptine treatment as palliation for prostate cancer: experimental and clinical evaluation

Bromocriptine, a potent antiprolactin, in conjunction with low dose polyestradiolphosphate or cyproterone acetate resulted in a response rate of 28 out of 42 patients. The longest response with pain free and physical as well as sexual, full activity was 15 months until relapse occurred. There was a clear cut prevention of gynecomaesia in 11 out of 13 patients. This is a second report on treatment for prostatic cancer with bromocriptine.